{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:35:55Z","timestamp":1792060555171,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Florida Infectious Disease and Immunology Departmental Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Dengue fever (DF), a leading arboviral disease globally, is caused by the Dengue virus (DENV) and represents a significant public health concern, with an estimated 390 million cases reported annually. Due to the complexity of the various dengue variants and the severity of the disease, vaccination emerges as the essential strategy for combating this widespread infectious disease. The absence of specific antiviral medications underscores the critical need for developing a Dengue vaccine. This review aims to present the current status and future prospects of Dengue vaccine development. Further, this review elaborates on the various strategies employed in vaccine development, including attenuated, inactivated, subunit, and viral vector vaccines. Each approach is evaluated based on its immunogenicity, safety, and efficacy, drawing on data from preclinical and clinical studies to highlight the strengths and limitations of each candidate vaccine. The current study sheds light on future directions and research priorities in developing Dengue vaccines. In conclusion, the development of a Dengue vaccine holds significant potential for reducing the global burden of DF. However, challenges remain in terms of vaccine safety, efficacy, delivery, and availability. Overcoming these challenges, coupled with advancements in vaccine technology, could lead to better control and prevention of Dengue, thereby enhancing public health and quality of life.<\/jats:p>","DOI":"10.3390\/v17020212","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:36:32Z","timestamp":1738560992000},"page":"212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Current Dengue Virus Vaccine Developments and Future Directions"],"prefix":"10.3390","volume":"17","author":[{"given":"Govindaraj","family":"Anumanthan","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-733X","authenticated-orcid":false,"given":"Bikash","family":"Sahay","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-6727","authenticated-orcid":false,"given":"Ayalew","family":"Mergia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, Z., Zhang, Q., Li, L., He, J., Guo, J., Wang, Z., Huang, Y., Xi, Z., Yuan, F., and Li, Y. (2023). The effect of temperature on dengue virus transmission by Aedes mosquitoes. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1242173"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4269\/ajtmh.11-0774","article-title":"Determinants of mortality from severe dengue in Brazil: A population-based case-control study","volume":"88","author":"Moraes","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Harapan, H., Michie, A., Sasmono, R.T., and Imrie, A. (2020). Dengue: A Minireview. Viruses, 12.","DOI":"10.3390\/v12080829"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7861\/clinmed.2021-0791","article-title":"Dengue infection: Global importance, immunopathology and management","volume":"22","author":"Kularatne","year":"2022","journal-title":"Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Screaton, G., and Mongkolsapaya, J. (2018). Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? the challenges of a dengue vaccine. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a029520"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"2","author":"Guzman","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Izmirly, A.M., Alturki, S.O., Connors, J., and Haddad, E.K. (2020). Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01055"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/B978-0-12-800098-4.00007-6","article-title":"Dengue virus vaccine development","volume":"88","author":"Yauch","year":"2014","journal-title":"Adv. Virus Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Norshidah, H., Vignesh, R., and Lai, N.S. (2021). Updates on dengue vaccine and antiviral: Where are we heading?. Molecules, 26.","DOI":"10.3390\/molecules26226768"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pinheiro-Michelsen, J.R., Souza, R.d.S.O., Santana, I.V.R., Silva, P.d.S.d., Mendez, E.C., Luiz, W.B., and Amorim, J.H. (2020). Anti-dengue Vaccines: From Development to Clinical Trials. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01252"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1128\/JVI.80.5.2170-2182.2006","article-title":"RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication","volume":"80","author":"Clyde","year":"2006","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2014.12.007","article-title":"Flavivirus reverse genetic systems, construction techniques and applications: A historical perspective","volume":"114","author":"Aubry","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rosales-Munar, A., Alvarez-Diaz, D.A., Laiton-Donato, K., Pel\u00e1ez-Carvajal, D., and Usme-Ciro, J.A. (2020). Efficient Method for Molecular Characterization of the 5\u2032 and 3\u2032 Ends of the Dengue Virus Genome. Viruses, 12.","DOI":"10.3390\/v12050496"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1101\/gad.1444206","article-title":"A 5\u2032 RNA element promotes dengue virus RNA synthesis on a circular genome","volume":"20","author":"Filomatori","year":"2006","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.mib.2008.06.004","article-title":"Structural proteomics of dengue virus","volume":"11","author":"Perera","year":"2008","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tremblay, N., Freppel, W., Sow, A.A., and Chatel-Chaix, L. (2019). The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek. Vaccines, 7.","DOI":"10.3390\/vaccines7040145"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-virology-110615-042334","article-title":"Properties and functions of the dengue virus capsid protein","volume":"3","author":"Byk","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1128\/JVI.00704-13","article-title":"Nucleolin Interacts with the Dengue Virus Capsid Protein and Plays a Role in Formation of Infectious Virus Particles","volume":"87","author":"Balinsky","year":"2013","journal-title":"J. Virol."},{"key":"ref_20","first-page":"836","article-title":"Dengue virus type-3 envelope protein domain III; expression and immunogenicity","volume":"17","author":"Fahimi","year":"2014","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chong, L.C., and Khan, A.M. (2019). Identification of highly conserved, serotype-specific dengue virus sequences: Implications for vaccine design. BMC Genom., 20.","DOI":"10.1186\/s12864-019-6311-z"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1567-1348(03)00004-2","article-title":"The origin, emergence and evolutionary genetics of dengue virus","volume":"3","author":"Holmes","year":"2003","journal-title":"Infect. Genet. Evol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-023-02072-5","article-title":"Genotyping of dengue virus from infected tissue samples embedded in paraffin","volume":"20","author":"Rivera","year":"2023","journal-title":"Virol. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4269\/ajtmh.13-0595","article-title":"Working Group on Dengue Clinical Presentation of Dengue by Serotype and Year of Epidemic in Martinique","volume":"91","author":"Thomas","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chawla, T., Chan, K.R., Zhang, S.L., Tan, H.C., Lim, A.P.C., Hanson, B.J., and Ooi, E.E. (2013). Dengue Virus Neutralization in Cells Expressing Fc Gamma Receptors. PLOS ONE, 8.","DOI":"10.1371\/journal.pone.0065231"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_28","first-page":"3","article-title":"Challenges on the development of a dengue vaccine: A comprehensive review of the state of the art","volume":"104","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hou, J., Ye, W., and Chen, J. (2022). Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.840104"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1021\/acs.jmedchem.5b01653","article-title":"The medicinal chemistry of dengue virus","volume":"59","author":"Behnam","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12688\/wellcomeopenres.15507.1","article-title":"Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. [version 1; peer review: 2 approved]","volume":"4","author":"Flasche","year":"2019","journal-title":"Wellcome Open Res"},{"key":"ref_34","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull. World Health Organ."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40506-023-00263-w","article-title":"Dengue: Update on clinically relevant therapeutic strategies and vaccines","volume":"15","author":"Rathore","year":"2023","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tricou, V., Essink, B., Ervin, J.E., Turner, M., Escudero, I., Rauscher, M., Brose, M., Lefevre, I., Borkowski, A., and Wallace, D. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLOS Neglected Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0011124"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-4-39","article-title":"Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2","volume":"4","author":"Blaney","year":"2004","journal-title":"BMC Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2046960","DOI":"10.1080\/21645515.2022.2046960","article-title":"A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-na\u00efve and flavivirus-experienced healthy adults","volume":"18","author":"Russell","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, Attenuated, Tetravalent Butantan\u2013Dengue Vaccine in Children and Adults","volume":"390","author":"Cintra","year":"2024","journal-title":"New Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/infdis\/jiaa603","article-title":"Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial","volume":"223","author":"Lin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1086\/503372","article-title":"Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination","volume":"193","author":"Sun","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4269\/ajtmh.1996.55.504","article-title":"Immunogenic and Protective Response in Mice Immunized with a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype Made in Fetal Rhesus Lung Cells","volume":"55","author":"Putnak","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Putnak","year":"2005","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2008.07.006","article-title":"Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice","volume":"26","author":"Babu","year":"2008","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0006-291X(03)01411-6","article-title":"The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs","volume":"308","author":"Zulueta","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00705-013-1639-1","article-title":"A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates","volume":"158","author":"Chen","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virusres.2008.08.008","article-title":"Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus","volume":"138","author":"Izquierdo","year":"2008","journal-title":"Virus Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhao, H., Jiang, T., Zhou, X.-Z., Deng, Y.-Q., Li, X.-F., Chen, S.-P., Zhu, S.-Y., Qin, E.-D., and Qin, C.-F. (2014). Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine. PLOS ONE, 9.","DOI":"10.1371\/journal.pone.0086573"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.apjtm.2017.03.003","article-title":"Towards development of a universal dengue vaccine\u2014How close are we?","volume":"10","author":"Pang","year":"2017","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Jaiswal","year":"2003","journal-title":"J Virol"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic Neutralizing Antibody Response to a Dengue Virus Type 2 DNA Vaccine by Incorporation of Lysosome-Associated Membrane Protein Sequences and Use of Plasmid Expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mintaev, R.R., Glazkova, D.V., Orlova, O.V., Ignatyev, G.M., Oksanich, A.S., Shipulin, G.A., and Bogoslovskaya, E.V. (2023). Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity. Vaccines, 11.","DOI":"10.3390\/vaccines11040831"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1128\/JVI.02298-12","article-title":"An Alphavirus Vector-Based Tetravalent Dengue Vaccine Induces a Rapid and Protective Immune Response in Macaques That Differs Qualitatively from Immunity Induced by Live Virus Infection","volume":"87","author":"White","year":"2013","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-74-1-89","article-title":"Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system","volume":"74","author":"Qu","year":"1993","journal-title":"J. Gen. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4269\/ajtmh.1994.50.472","article-title":"Immunization of Monkeys with Baculovirus-Dengue Type-4 Recombinants Containing Envelope and Nonstructural Proteins: Evidence of Priming and Partial Protection","volume":"50","author":"Eckels","year":"1994","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/BA20080074","article-title":"Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice","volume":"52","author":"Lazo","year":"2009","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Jeffrey","year":"2011","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ramasamy, V., Arora, U., Shukla, R., Poddar, A., Shanmugam, R.K., White, L.J., Mattocks, M.M., Raut, R., Perween, A., and Tyagi, P. (2018). A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLOS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006191"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e01485-19","DOI":"10.1128\/mBio.01485-19","article-title":"Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies","volume":"10","author":"Gallichotte","year":"2019","journal-title":"mBio"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e01181-17","DOI":"10.1128\/JVI.01181-17","article-title":"An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design","volume":"91","author":"Urakami","year":"2017","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wollner, C.J., Richner, M., Hassert, M.A., Pinto, A.K., Brien, J.D., and Richner, J.M. (2021). A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. J. Virol., 95.","DOI":"10.1128\/JVI.02482-20"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_73","first-page":"99","article-title":"HLA and other gene associations with dengue disease severity","volume":"338","author":"Stephens","year":"2010","journal-title":"HLA and other gene associations with dengue disease severity. Curr. Top. Microbiol. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmhg.2012.08.003","article-title":"Non-HLA gene polymorphisms and their implications on dengue virus infection","volume":"14","author":"Harapan","year":"2013","journal-title":"Egypt. J. Med Hum. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"McKechnie, J.L., Beltr\u00e1n, D., Pitti, A., Saenz, L., Ara\u00faz, A.B., Vergara, R., Harris, E., Lanier, L.L., Blish, C.A., and L\u00f3pez-Verg\u00e8s, S. (2019). HLA Upregulation During Dengue Virus Infection Suppresses the Natural Killer Cell Response. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00268"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1381612823666170913163904","article-title":"Development of peptide vaccines in dengue","volume":"24","author":"Reginald","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.4161\/21645515.2014.980210","article-title":"Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals","volume":"10","author":"Comber","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gupta, S., Agarwal, A., Kumar, A., and Biswas, D. (2018). Genome-wide analysis to identify HLA factors potentially associated with severe dengue. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00728"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10989-021-10184-1","article-title":"Top down computational approach: A vaccine development step to find novel superantigenic HLA binding epitopes from dengue virus proteome","volume":"27","author":"Sharma","year":"2021","journal-title":"Int. J. Pept. Res. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:07Z","timestamp":1760027107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020212"],"URL":"https:\/\/doi.org\/10.3390\/v17020212","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}